For research use only. Not for therapeutic Use.
SSTC3（Cat No.:I015549）is a small-molecule inhibitor that targets the steroid receptor coactivator (SRC) family, particularly SRC-3, which plays a key role in regulating transcriptional activity of nuclear hormone receptors. By inhibiting SRC-3, SSTC3 disrupts the coactivation of receptors involved in cancer cell proliferation, hormone signaling, and metabolic regulation. This makes it a promising compound for cancer research, particularly in cancers that are driven by hormonal pathways such as breast and prostate cancers. SSTC3 is widely used in studies exploring therapeutic strategies for targeting transcriptional coactivators in cancer treatment.
| Catalog Number | I015549 |
| CAS Number | 1242422-09-8 |
| Molecular Formula | C₂₃H₁₇F₃N₄O₃S₂ |
| Purity | ≥95% |
| IUPAC Name | 4-[methyl-[4-(trifluoromethyl)phenyl]sulfamoyl]-N-(4-pyridin-2-yl-1,3-thiazol-2-yl)benzamide |
| InChI | InChI=1S/C23H17F3N4O3S2/c1-30(17-9-7-16(8-10-17)23(24,25)26)35(32,33)18-11-5-15(6-12-18)21(31)29-22-28-20(14-34-22)19-4-2-3-13-27-19/h2-14H,1H3,(H,28,29,31) |
| InChIKey | HSFAATUFWDDUGW-UHFFFAOYSA-N |
| SMILES | CN(C1=CC=C(C=C1)C(F)(F)F)S(=O)(=O)C2=CC=C(C=C2)C(=O)NC3=NC(=CS3)C4=CC=CC=N4 |
| Reference | [1]. Li B, et al, Differential abundance of CK1α provides selectivity for pharmacological CK1α activators to target WNT-dependent tumors. Sci Signal. 2017 Jun 27;10(485). pii: eaak9916. |
